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LETTER TO THE EDITOR
Novel Mutations in the Von Hippel–Lindau Gene Associated with Congenital
Polycythemia
To the editor: Polycythemia is a rare disorder in children and the
vast majority of cases are secondary to causes such as cyanotic
congenital heart disease, congenital lung diseases, liver and kidney
disease, and masses producing erythropoietin. Mutations in exon 3
of the VHL gene are the most common cause of congenital
erythrocytosis [1–3]. Several reports have shown evidence of
heterozygous and homozygousmutations in exon 2 of theVHL gene
as a cause of congenital polycythemia [4–6].
We report on a 9-month-old female who was referred to the
hematology clinic for evaluation by her pediatrician with plethora
and erythrocytosis (RBC count 7.67million/mm3, hemoglobin
21.5 g/dL, hematocrit 66.2%, MCV 86.3 fL). The erythropoietin
level was 48 IU/L (normal 4–27), in the face of marked
erythrocytosis. The patient was started on phlebotomy treatments
of 5ml/kg of blood which has progressed to 10ml/kg of blood with
normal saline replacement every 4weeks with good results. Shewas
Fig. 1. Parental sequence analysis of exon 2 of the VHL gene showed that the patient carries a paternally inherited c.662A>G (p.Asn150Ser) and a
de novo c.646C>T (p.Gln145X) mutation (arrows). The hemoglobin levels are denoted in the sequence reads.
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started on ferrous sulfate supplementation which continues till date
for iron deficiency secondary to phlebotomy.
After a thorough evaluation for secondary causes of polycythe-
mia ruled out cyanotic congenital heart disease, congenital lung
diseases, liver or kidney disease, and masses producing erythropoi-
etin, von Hippel–Lindau (VHL) gene sequencing analysis was
performed. Our patient carries a paternally inherited [c.662A>G (p.
Asn150Ser)] and a denovo (c.646C>T [p.Gln145X]) mutation,
previously reported in VHL patients [7] (Fig. 1). In silico analysis
using theNCBIHomoloGene tool for orthologous sequences for the
VHL gene shows the two residues to be conserved amongst species.
The de novo mutation leads to a premature stop codon and is
predicted to result in a non-functional protein. We believe the
paternally inherited mutation (c.662A>G [p.Asn150Ser]) alters
interaction of the VHL protein with HIF-2 alpha (Hypoxia-
Inducible Factor) leading to clinical manifestations seen in the
proband. The details of the interaction are outside the scope of the
present report. VHL syndrome is a highly penetrant autosomal
dominant disorder associated with tumors such as pheochromocy-
toma and hemangioblastomas of the retina, liver and cerebellum. To
date, at age 9, our patient does not exhibit any of these
manifestations. Patients with Chuvash polycythemia have frequent
thrombotic events which have not been reported in either the
proband or her father [6]. Previous reports have demonstrated
mutations in exon 3 of the VHL gene, including Chuvash
polycythemia [8]. Few reports have shown both heterozygous
and homozygous mutations in exon 2 of the VHL gene leading to
congenital polycythemia [4–6]. Our case adds to the present
literature of growing evidence of exon 2 mutations, validating the
importance of VHL mutational analysis in children as part of
workup for congenital polycythemia. Based on our patient and
previous reports, these exon 2 mutations do not seem to predispose
either the proband or their carrier parents to an increased risk for
VHL-related tumors. Additional studies will be required to
elucidate the molecular basis and genotype–phenotype correlation
of these mutations that has a potential to greatly impact the
surveillance guidelines for VHL-associated tumors.
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